China Resources Double-Crane Pharmaceutical (600062.SH) Receives Approval for Pioglitazone Hydrochloride Dispersible Tablets

Stock News12-01

China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its subsidiary, Shuanghe Tian'an Pharmaceutical (Guizhou) Co., Ltd., recently received the "Drug Supplement Approval Notice" for Pioglitazone Hydrochloride Dispersible Tablets from the National Medical Products Administration. After review, the drug is deemed to have passed the consistency evaluation of generic drug quality and efficacy. Pioglitazone Hydrochloride Dispersible Tablets are used to treat type 2 diabetes. Passing the consistency evaluation will enhance future market sales and competitiveness while accumulating valuable experience for subsequent generic drug consistency evaluations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128972090?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 17:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128972090","market":"fut","top_or_hot":-1,"title":"China Resources Double-Crane Pharmaceutical (600062.SH) Receives Approval for Pioglitazone Hydrochloride Dispersible Tablets","media":"Stock News","content":"<p>China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its subsidiary, Shuanghe Tian'an Pharmaceutical (Guizhou) Co., Ltd., recently received the \"Drug Supplement Approval Notice\" for Pioglitazone Hydrochloride Dispersible Tablets from the National Medical Products Administration. After review, the drug is deemed to have passed the consistency evaluation of generic drug quality and efficacy. Pioglitazone Hydrochloride Dispersible Tablets are used to treat type 2 diabetes. Passing the consistency evaluation will enhance future market sales and competitiveness while accumulating valuable experience for subsequent generic drug consistency evaluations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Resources Double-Crane Pharmaceutical (600062.SH) Receives Approval for Pioglitazone Hydrochloride Dispersible Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Resources Double-Crane Pharmaceutical (600062.SH) Receives Approval for Pioglitazone Hydrochloride Dispersible Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-01 17:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its subsidiary, Shuanghe Tian'an Pharmaceutical (Guizhou) Co., Ltd., recently received the \"Drug Supplement Approval Notice\" for Pioglitazone Hydrochloride Dispersible Tablets from the National Medical Products Administration. After review, the drug is deemed to have passed the consistency evaluation of generic drug quality and efficacy. Pioglitazone Hydrochloride Dispersible Tablets are used to treat type 2 diabetes. Passing the consistency evaluation will enhance future market sales and competitiveness while accumulating valuable experience for subsequent generic drug consistency evaluations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0175","symbol_name":"白马股","start_time":0,"source_url":"","article_id":"1128972090","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128972090","pubTimestamp":1764581056,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its subsidiary, Shuanghe Tian'an Pharmaceutical (Guizhou) Co., Ltd., recently received the \"Drug Supplement Approval...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600062":"华润双鹤","BK0175":"白马股","BK0010":"央企","BK0028":"国家队","BK0185":"二线龙头","BK0239":"医药制造","BK0188":"融资融券"},"translate_title":"华润双鹤药业（600062.SH）盐酸吡格列酮分散片获批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600062":1},"content_text":"China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its subsidiary, Shuanghe Tian'an Pharmaceutical (Guizhou) Co., Ltd., recently received the \"Drug Supplement Approval Notice\" for Pioglitazone Hydrochloride Dispersible Tablets from the National Medical Products Administration. After review, the drug is deemed to have passed the consistency evaluation of generic drug quality and efficacy. Pioglitazone Hydrochloride Dispersible Tablets are used to treat type 2 diabetes. Passing the consistency evaluation will enhance future market sales and competitiveness while accumulating valuable experience for subsequent generic drug consistency evaluations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128972090","isCrawlerRequest":true}